RGC Company Profile and Key Details

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Regencell Bioscience Holdings Limited generated EPS of -$0.01 over the past year. Five-year average earnings growth is -33.47%.

Short-term trend indicators are bearishly aligned (SMA20 -6.68%, SMA50 -6.46%, SMA200 37.55%). The stock’s 14-day RSI is 46.03 (neutral), while the ATR of 3.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.55% below its high and over 24938.1% above its low. Average 10-day trading volume of 285.49 thousand shares is below the 3-month average of 438.35 thousand, indicating normal recent market interest.

Regencell Bioscience Holdings Limited has 494.49 million shares outstanding. The public float is 18.43 million shares, elevated short interest at 2.45% of float. This equals 2.26 million shares. The short ratio is 4.15 days. Institutional investors hold 3.64% of the float. Insiders own 96.16%. MILES AMY E holds 588.40 thousand shares, Ownby David has 229.57 thousand shares and BRANDOW PETER B has 212.72 thousand shares.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) closed at $30.80 USD, losing -$2.92 (-8.66%) from the previous close of $33.72. The stock is currently mid-range between its 52-week high and low $0.62 and $83.60. With a market capitalization of about $15.23 billion, Regencell Bioscience Holdings Limited is classified as a large-cap and shows higher-than-market volatility (beta ~2.25). Key stats such as the average daily volume over the past year has been around 424.26 thousand shares, in line with its 52-week average. Headquartered in Causeway Bay, None, Regencell Bioscience Holdings Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Yat-Gai Au, the company employs approximately 12 people and listed since July 16, 2021. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.

Regencell Bioscience Holdings Limited trades at a P/E ratio of -4249.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3133.62 reflecting a rich premium to book value. The P/FCF stands at 0.0, also below market averages. Compared to sector medians, Regencell Bioscience Holdings Limited P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares are up 15.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Regencell Bioscience Holdings Limited trading at a premium to the broader market with a P/E of -4249.26. Our AI forecast model points to short-term strength (0.45% over two weeks), a medium-term rise (17.79% over three months), and a longer-term gain (33.83% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Regencell Bioscience Holdings Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.45%, with price expected at $30.94 by April 16, 2026, within a range of $28.39 to $33.35 3-Month Outlook: Projected rise of 17.79%, reaching $36.28 by July 01, 2026, with a range of $27.50 to $39.90. 1-Year Outlook: Projected gain of 33.83%, with price at $41.22 by April 02, 2027, within a range of $38.64 to $43.60.